Lambert Nicole 4

What Happened Nicole Lambert, a director of Arcus Biosciences (RCUS), was granted 5,700 restricted stock units (RSUs) and a 16,900-share derivative award (option) on June 11, 2026. Both awards are reported as acquisitions at $0 on the Form 4 because they are compensation grants rather than open-market purchases.

Key Details

• Transaction date: 2026-06-11; Form 4 filed 2026-06-12 (appears timely).
• Awards: 5,700 RSUs (non-derivative) and 16,900 derivative shares (option-like award), both recorded at $0.
• Vesting (Footnotes): Both grants vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders; both become fully vested in the event of a change in control (F1, F2).
• Shares owned after transaction: Not reported on this Form 4.
• Transaction code: A = award/grant. The derivative entry reflects an option-style award that will become exercisable upon vesting or change in control.

Context These awards are typical director compensation and do not represent an open-market buy or sell. Because the 16,900-share item is a derivative grant (option-like), it conveys a future right to acquire shares subject to vesting/exercise conditions rather than immediate ownership. Such grants are routine but will dilute outstanding shares if exercised.